Navigation Links
JumpStart Invests in Checkpoint Surgical

CLEVELAND, Nov. 10 /PRNewswire/ -- JumpStart Inc., the Northeast Ohio venture development organization that accelerates the progress of high growth early-stage businesses, announced a JumpStart Ventures investment commitment of $250,000 in Checkpoint Surgical, LLC. A spinout of NDI Medical, the Highland Hills, OH medical device company is developing and commercializing a surgical handheld disposable nerve stimulator.

(Logo: )

Nerve stimulators are used to locate, identify, and confirm motor nerve function and help surgeons avoid nerve damage during surgical procedures. Checkpoint Surgical's device, called the CHECKPOINT® Stimulator/Locator, combines the broad functionality of traditional console-based devices with the convenience and control of a handheld device.

"Right now, there is no device on the market that combines the broad functionality of console-based devices with the control of a handheld device," said Lee Poseidon, the JumpStart Venture Partner who will be working with the company. "Checkpoint Surgical has several patents pending around the use of a safe, biphasic current, handheld device with broad, adjustable stimulus parameters, which will give their product competitive advantage."

"The CHECKPOINT® Stimulator/Locator is an important tool that helps surgeons quickly and reliably locate nerves and evaluate nerve function during surgery. With the aid of our tool, physicians can make surgical decisions with confidence. It also allows surgeons to reliably confirm and document nerve integrity at the conclusion of surgery," said Len Cosentino, Chief Executive Officer of Checkpoint Surgical. "JumpStart's funding will help support our pilot launch effort that will demonstrate market acceptance and provide other useful market data over the next few months leading up to a full commercial launch in mid 2010."

This is JumpStart Ventures' 54th investment in its 41st company. Other healthcare companies in JumpStart Ventures' portfolio include AnalizaDx, CardioInsight Technologies, CerviLenz, Freedom Meditech, Great Lakes Pharmaceuticals, Juventas Therapeutics, Neuros Medical, Synapse Biomedical, Tursiop Technologies, and VasoLux MicroSystems.

About Checkpoint Surgical LLC

The mission of Checkpoint Surgical ( is to provide physicians with medical devices to locate, evaluate and protect nerves and muscles in surgical procedures for better patient outcomes. The Company's flagship product, the CHECKPOINT® Stimulator/Locator is a single-use, hand-held stimulator with a broad range of stimulation parameters that are fully controllable by the surgeon. The CHECKPOINT® Stimulator/Locator was designed by a world class team of orthopaedic surgeons and biomedical engineers working together to provide surgeons with a simple, safe, versatile tool to help locate, identify and evaluate nerves in the surgical site and make surgical decisions with confidence. Beyond this initial product, the Checkpoint surgical team is dedicated to continue to develop new and innovative first in class devices to help surgeons achieve better patient outcomes.

About JumpStart Inc.

JumpStart ( is a nationally recognized venture development organization that accelerates the progress of high potential, early-stage businesses and includes a special focus on diverse entrepreneurs working in the highest growth industries. Through the depth of its entrepreneurial team and the breadth of its high value resources, JumpStart improves client success in achieving significant milestones, including raising the follow-on capital necessary to create wealth. JumpStart strives to create a more prosperous future for Northeast Ohio. As part of its robust public/private partnership model, JumpStart recognizes the integral support of Ohio's Third Frontier Project, the state's largest-ever commitment to expanding Ohio's high tech research, innovation, commercialization, and company formation activities, which are increasing opportunities for all Ohioans.

SOURCE JumpStart, Inc.

SOURCE JumpStart, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
2. Kansas Invests Millions in Innovations to Improve Human Health and Launches Three National Bioscience Programs at BIO08
3. 7 Health Ventures Invests in Tulip Medical
4. Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments
5. Merial invests US $70 million in Nanchang, China
6. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
8. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
9. New Non-Surgical Stem-Cell Procedure to Relieve Chronic Tendon Problems
10. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
11. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
Post Your Comments:
(Date:11/24/2015)... November 24, 2015 F1000Workspace - ... - since it was launched just six months ago. ... and authoring platform for scientists - since it was launched ... have been loaded on to F1000Workspace - a ... since it was launched just six months ago. ...
(Date:11/24/2015)... YORK , Nov. 24, 2015 iRhythm Technologies, ... advancing cardiac care, today announced that it will participate in the ... Hotel in New York, NY . ... present on Tuesday December 1, 2015 at 8:50am ET. ... . --> . ...
(Date:11/24/2015)... uptake of recently approved and pipeline premium products for Type 1 Diabetes ... says GBI Research . --> The ... Mellitus (T1DM), will be a key driver of market growth to 2021, ... The uptake of recently approved and pipeline premium products for Type 1 ... 2021, says GBI Research . Type ...
Breaking Medicine Technology:
(Date:11/24/2015)... , ... November 24, 2015 , ... In an ... restrictions and variables that determine which patients are or are not eligible for bariatric ... have a BMI over 40, are more than 100 pounds overweight, or have a ...
(Date:11/24/2015)... UT (PRWEB) , ... November 24, 2015 , ... It ... Magazine. For a business, it is critical that the first impression be positive and ... they are not likely to buy anything or want to return. They will also ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... gather to share their knowledge and experiences at a live taping of the ... Ruesch Center for the Cure of Gastrointestinal Cancers 2015 Symposium at Georgetown University ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Aided by ... today announced an innovative study designed to yield insights into how to detect and ... of biomarkers for pancreatic cancer from small, non-coding RNA molecules (ncRNA), genetic material that ...
(Date:11/24/2015)... ... November 24, 2015 , ... Sir Grout of Baltimore is ... certification. The award recognizes good companies for excellence in service and a commitment ... and hard surface restoration company earned this recognition after a thorough review by ...
Breaking Medicine News(10 mins):